Model Name
Neisseria gonorrhoeae (FA1090 ATCC 700825), Vaginal Infection Model

Item Number
608600

Introduction
This assay evaluates the antimicrobial efficacy of test articles in a mouse vaginal infection model with Neisseria gonorrhoeae (FA1090 ATCC 700825). The microbial counts in vaginal lavage fluid are measured. Neisseria gonorrhoeae is a Gram-negative bacterium responsible for gonorrhea. Strain ATCC 700825, otherwise known as FA1090, is commonly reported in the literature for mouse pathogenesis studies.

Procedure Summary
Groups of 5 ovariectomize mice are used. Estrogen supplementation is supplied with 17β-estradiol administration. Animals are intravaginally inoculated with pathogen suspension. Test articles and vehicle are administered 2 hours after inoculation. (Doses may be administered IV, SC, PO, IM, or IP.) At time points, animals are humanely euthanized, vaginal lavage is performed and the pathogen burden in lavage fluid is measured. Pathogen counts from treatment groups are compared to vehicle groups and the significance of an effect is determined.

Turnaround Time(s)
6 weeks from sample receipt

Literature
Vaccine p. 5741–5751, 2008

Optional Services
Analysis of cytokines (with Luminex) and PK exposure can be performed upon request. Histopathology of tissue samples may also be performed.

Related Assay(s)  (Item # - Assay Name - Species)
612501* - Neisseria gonorrhoeae (ATCC 700825) MIC - Bacteria
*provided by partner lab Eurofins Pharma Discovery Services

Modified Protocols
We will readily accommodate client-specified alterations.

Laboratory
These assays are performed at our AAALAC accredited BSL2 laboratory in Taipei, Taiwan.

Animal Welfare
All aspects of this work is performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

Reference Compound(s)
Ciprofloxacin, Ceftriaxone

Last modified November 20, 2017

For current details about our Company address and contact information, please reference our website http://www.pharmacologydiscoveryservices.com/company-info/